<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145844</url>
  </required_header>
  <id_info>
    <org_study_id>HEPCTURKEY</org_study_id>
    <nct_id>NCT03145844</nct_id>
  </id_info>
  <brief_title>Direct Acting Agents in Hepatitis C Patients</brief_title>
  <acronym>HEPCTURKEY</acronym>
  <official_title>Evaluation of Efficacy and Safety of Direct Acting Agents in Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fehmi Tabak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Viral Hepatitis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viral Hepatitis Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective study conducted at 36 sites. Planned target patient number is
      1000.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 36 centers will be included in Turkey. Centers will be selected from clinics of
      infection and clinical microbiology. The inclusion of 1000 patients was targeted. All data
      will be retrospectively collected from the medical records of the patients. Patient visit is
      not necessary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease management with direct acting agents</measure>
    <time_frame>Beginning of treatment - 12 weeks after the treatment ended (36 weeks)</time_frame>
    <description>To assess disease management of chronic hepatitis C patients using direct acting agents (DAA) at national level, especially change in HCVRNA levels 12 weeks after the 24 weeks treatment (SVR12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Adverse event list according to CTCAE v.4.03</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2700</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C Relapse</condition>
  <condition>Hepatitis C Recurrent</condition>
  <arm_group>
    <arm_group_label>Direct Acting Agents</arm_group_label>
    <description>No Intervention</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients diagnosed as Hepatitis C and used direct acting agents.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who used direct acting agents for Hepatitis C

        Exclusion Criteria:

          -  Patients younger then 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fehmi Tabak, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Viral Hepatitis Society</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tansu Yamazhan, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Viral Hepatitis Society</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Viral Hepatitis Society</investigator_affiliation>
    <investigator_full_name>Fehmi Tabak</investigator_full_name>
    <investigator_title>Prof. Fehmi Tabak</investigator_title>
  </responsible_party>
  <keyword>DAA</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

